Celldex Therapeutics (NASDAQ: CLDX) is a clinical-stage biopharmaceutical company focused on mast cell biology and the development of therapeutic antibodies targeting severe inflammatory, allergic, and autoimmune diseases. The company generates no product revenue as of its FY2025 10-K (filed 2026-02-25); it is pre-commercial and funds operations through capital markets activity and, potentially, partnership arrangements. Its pipeline centers on monoclonal and bispecific antibodies designed to address mast cell mediated diseases where existing treatments are inadequate. Celldex's stated strategy is to retain full economic rights to its therapies or pursue commercial partnerships on favorable terms, preserving optionality on how each asset reaches patients. The company is headquartered in the United States and trades on the Nasdaq Capital Market. No product approvals or commercial revenue are disclosed in the FY2025 filing, placing Celldex squarely in the R&D-expenditure phase of the biopharmaceutical development cycle.

Revenue model

No commercial product revenue disclosed in the FY2025 10-K (filed 2026-02-25). The company is pre-commercial, relying on capital raises and potential future partnership or licensing arrangements to fund R&D operations.

Products and services

Pipeline of monoclonal and bispecific antibody drug candidates targeting mast cell mediated diseases, including severe inflammatory, allergic, and autoimmune conditions. Specific program names were not enumerated in the provided filing excerpts.

Customers and end markets

Patients with severe inflammatory, allergic, autoimmune, and other diseases for which available treatments are inadequate. No commercial customers as of FY2025; end market is specialty therapeutics in immunology and allergy.

Value-chain role

Drug discovery and clinical-stage development company. Operates upstream of commercialization; conducts research and runs clinical development programs internally, with the option to partner for late-stage development or commercialization.

Geographic exposure

Headquartered in the United States. No geographic revenue breakdown disclosed in the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-25

Industry: In Vitro & In Vivo Diagnostic Substances Peers: BridgeBio Pharma Inc Veracyte Inc Catalyst Pharmaceuticals Inc Day One Biopharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP Ligand Pharmaceuticals Inc Syndax Pharmaceuticals Inc Vaxcyte Inc Xencor Inc